サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：治療薬モニタリング市場：製品別、技術別、薬物クラス別、エンドユーザー別：世界の機会分析と産業予測、2021-2031年
市場調査レポート
商品コード
1266385

治療薬モニタリング市場：製品別、技術別、薬物クラス別、エンドユーザー別：世界の機会分析と産業予測、2021-2031年

Therapeutic Drug Monitoring Market By Product, By Technology, By Drug Class, By End Users : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 292 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
治療薬モニタリング市場：製品別、技術別、薬物クラス別、エンドユーザー別：世界の機会分析と産業予測、2021-2031年
出版日: 2023年02月01日
発行: Allied Market Research
ページ情報: 英文 292 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

治療薬モニタリングの世界市場は、2021年に19億3,293万米ドルと評価され、2022年から2031年にかけて8.5%のCAGRで成長し、2031年には44億1,530万米ドルに達すると予測されています。

治療薬モニタリング（TDM）は、患者の血液中の特定の薬物の濃度を測定し、投与レジメンや治療を最適化し、毒性を最小限に抑えるための臨床実践です。治療薬モニタリングは、薬物代謝の個人差を考慮し、毒性のリスクを最小限に抑え、薬物相互作用を特定・管理し、薬物治療の安全性と有効性を向上させるために使用されます。薬物治療の管理における貴重なツールであり、安全性、有効性、個別化されたケアの面で多くの利点を提供します。治療薬の濃度は、免疫測定法、熱量測定法、クロマトグラフィー質量分析法などでモニターされます。

治療薬モニタリング市場の成長は、慢性疾患の有病率の増加、治療薬モニタリングに関する意識の高まり、新興市場における治療薬モニタリングサービスの需要増によってもたらされます。心血管疾患、がん、神経変性疾患など、治療域の狭い薬剤による長期的な治療が必要な慢性疾患の有病率の増加が、治療薬モニタリングサービスの需要を促進しています。例えば、国際糖尿病連合によると、2021年には、世界で約5億3,700万人の成人（20～79歳）が糖尿病を患っていると推定されており、2030年には6億4,300万人に達すると予想されています。このように、慢性疾患の有病率の増加や長期的な治療の必要性から、治療薬モニタリングサービスの需要が高まり、ひいては市場成長に寄与することが期待されます。さらに、イムノアッセイなどの先進的かつ革新的な消耗品への需要の高まりが、市場成長の主な要因となっています。例えば、Eagle Biosciences社は、患者の血液中のAlemtuzumab（Lemrada）薬剤を定量的に測定するために使用されるAlemtuzumab ELISA Assayなどの様々な治療薬モニタリングアッセイを提供しています。しかし、市場には熟練した専門家がおらず、サンプル採取時の技術的エラーもあるため、治療薬モニタリング製品の採用が制限され、ひいては今後の市場成長の妨げとなる可能性があります。一方、治療薬モニタリングの研究開発活動への注力や新興国市場の成長機会は、予測期間中に治療薬モニタリングに大きな機会をもたらすと期待されています。

治療薬モニタリング市場は、製品、技術、薬物クラス、エンドユーザー、地域によって区分されます。製品別では、市場は消耗品と機器に分類されます。技術別では、市場はイムノアッセイ、クロマトグラフィー-スペクトロメトリー、その他に区分されます。薬剤クラス別では、抗てんかん薬、抗生物質薬、抗不整脈薬、免疫抑制剤、その他に分類されます。

エンドユーザー別では、市場は病院、診断ラボ、研究・学術機関に分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州地域）、アジア太平洋（中国、日本、インド、オーストラリア、韓国、その他アジア太平洋地域）、LAMEA（ブラジル、サウジアラビア、南アフリカ、その他LAMEA）で分析されています。世界の治療薬モニタリング市場で活動する主な主要企業は、Abbott Laboratories、Biomerieux SA、Bio-Rad Laboratories, Inc、Chromsystems Instruments &Chemicals GmbH、Danaher Corporation、Exagen Inc、F. Hoffmann-La Roche Ltd、Sekisui Chemical Co Ltd.、Siemens AG、Thermo Fisher Scientific Inc.

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • トップインパクトファクター
    • トップインベストメントポケット
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • ライバルの強さ
  • 市場力学
    • 促進要因
      • 慢性疾患の有病率の増加
      • プレシジョンメディシンの導入の増加
      • 技術進歩の高まり
    • 抑制要因
      • 熟練したプロフェッショナルの不足
    • 機会
      • 新興経済諸国における高い成長性
  • COVID-19市場への影響度分析

第4章 治療薬モニタリング市場：製品別

  • 概要
    • 市場規模・予測
  • 消耗品
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • 設備
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析

第5章 治療薬モニタリング市場：技術別

  • 概要
    • 市場規模・予測
  • イムノアッセイ
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • クロマトグラフィー - 分光分析
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • その他
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析

第6章 治療薬モニタリング市場：薬効薬物クラス別

  • 概要
    • 市場規模・予測
  • 抗てんかん薬
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • 抗不整脈薬
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • 免疫抑制薬
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • 抗生物質剤
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • その他
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析

第7章 治療薬モニタリング市場：エンドユーザー別

  • 概要
    • 市場規模・予測
  • 病院
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • 診断用ラボ
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • 調査機関・学術機関
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析

第8章 治療薬モニタリング市場：地域別

  • 概要
    • 市場規模・予測：地域別
  • 北米
    • 主な動向と機会
    • 市場規模・予測：製品別
    • 市場規模・予測：技術別
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
      • 米国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
      • カナダ
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
      • メキシコ
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
  • 欧州
    • 主な動向と機会
    • 市場規模・予測：製品別
    • 市場規模・予測：技術別
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
      • ドイツ
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
      • フランス
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
      • 英国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
      • イタリア
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
      • スペイン
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
      • その他欧州
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
  • アジア太平洋地域
    • 主な動向と機会
    • 市場規模・予測：製品別
    • 市場規模・予測：技術別
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
      • 日本
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
      • 中国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
      • オーストラリア
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
      • インド
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
      • 韓国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
      • その他アジア太平洋地域
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
  • LAMEA
    • 主な動向と機会
    • 市場規模・予測：製品別
    • 市場規模・予測：技術別
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
      • ブラジル
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
      • サウジアラビア
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
      • 南アフリカ
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別
      • LAMEAの残りの地域
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：エンドユーザー別

第9章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • トップ企業のポジショニング、2021年

第10章 企業プロファイル

  • Bio-Rad Laboratories, Inc.
  • Siemens AG
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Biomerieux SA
  • Danaher Corporation
  • Exagen Inc.
  • Thermo Fisher Scientific Inc.
  • SEKISUI CHEMICAL CO., LTD.
  • Chromsystems Instruments & Chemicals GmbH
図表

LIST OF TABLES

  • TABLE 01. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 02. THERAPEUTIC DRUG MONITORING MARKET FOR CONSUMABLES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. THERAPEUTIC DRUG MONITORING MARKET FOR EQUIPMENT, BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 05. THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-SPECTROMETRY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 07. THERAPEUTIC DRUG MONITORING MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 08. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 09. THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. THERAPEUTIC DRUG MONITORING MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 15. THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. THERAPEUTIC DRUG MONITORING MARKET FOR DIAGNOSTIC LABS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. THERAPEUTIC DRUG MONITORING MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 19. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 20. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 21. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 22. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 23. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 24. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 25. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 26. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 27. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 28. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 29. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 30. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 31. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 32. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 33. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 34. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 35. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 36. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 37. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 38. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 39. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 40. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 41. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 42. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 43. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 44. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 45. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 46. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 47. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 48. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 49. UK THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 50. UK THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 51. UK THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 52. UK THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 53. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 54. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 55. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 56. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 57. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 58. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 59. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 60. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 61. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 62. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 63. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 64. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 65. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 66. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 67. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 68. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 69. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 70. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 71. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 72. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 73. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 74. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 75. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 76. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 77. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 78. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 79. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 80. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 81. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 82. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 83. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 84. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 85. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 86. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 87. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 88. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 89. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 90. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 91. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 92. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 93. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 94. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 95. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 96. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 97. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 98. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 99. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 100. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 101. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 102. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 103. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 104. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 105. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 106. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 107. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 108. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 109. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 110. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 111. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 112. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
  • TABLE 113. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 114. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
  • TABLE 115. BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES
  • TABLE 116. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 117. BIO-RAD LABORATORIES, INC.: PRODUCT SEGMENTS
  • TABLE 118. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 119. BIO-RAD LABORATORIES, INC.: KEY STRATERGIES
  • TABLE 120. SIEMENS AG: KEY EXECUTIVES
  • TABLE 121. SIEMENS AG: COMPANY SNAPSHOT
  • TABLE 122. SIEMENS AG: PRODUCT SEGMENTS
  • TABLE 123. SIEMENS AG: PRODUCT PORTFOLIO
  • TABLE 124. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 125. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 126. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 127. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 128. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 129. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 130. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 131. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 132. BIOMERIEUX SA: KEY EXECUTIVES
  • TABLE 133. BIOMERIEUX SA: COMPANY SNAPSHOT
  • TABLE 134. BIOMERIEUX SA: PRODUCT SEGMENTS
  • TABLE 135. BIOMERIEUX SA: PRODUCT PORTFOLIO
  • TABLE 136. DANAHER CORPORATION: KEY EXECUTIVES
  • TABLE 137. DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 138. DANAHER CORPORATION: PRODUCT SEGMENTS
  • TABLE 139. DANAHER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 140. EXAGEN INC.: KEY EXECUTIVES
  • TABLE 141. EXAGEN INC.: COMPANY SNAPSHOT
  • TABLE 142. EXAGEN INC.: PRODUCT SEGMENTS
  • TABLE 143. EXAGEN INC.: PRODUCT PORTFOLIO
  • TABLE 144. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 145. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 146. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
  • TABLE 147. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 148. SEKISUI CHEMICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 149. SEKISUI CHEMICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 150. SEKISUI CHEMICAL CO., LTD.: PRODUCT SEGMENTS
  • TABLE 151. SEKISUI CHEMICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 152. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: KEY EXECUTIVES
  • TABLE 153. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: COMPANY SNAPSHOT
  • TABLE 154. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: PRODUCT SEGMENTS
  • TABLE 155. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. THERAPEUTIC DRUG MONITORING MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF THERAPEUTIC DRUG MONITORING MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN THERAPEUTIC DRUG MONITORING MARKET (2022-2031)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALTHERAPEUTIC DRUG MONITORING MARKET
  • FIGURE 10. THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR CONSUMABLES, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR EQUIPMENT, BY COUNTRY 2021-2031(%)
  • FIGURE 13. THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY 2021-2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-SPECTROMETRY, BY COUNTRY 2021-2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 17. THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY 2021-2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY 2021-2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 23. THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL, BY COUNTRY 2021-2031(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR DIAGNOSTIC LABS, BY COUNTRY 2021-2031(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY 2021-2031(%)
  • FIGURE 27. THERAPEUTIC DRUG MONITORING MARKET BY REGION, 2021
  • FIGURE 28. U.S. THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. CANADA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. MEXICO THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. GERMANY THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. FRANCE THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. UK THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. ITALY THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. SPAIN THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. JAPAN THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. CHINA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. INDIA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 44. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 45. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 46. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
  • FIGURE 47. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 50. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 51. COMPETITIVE DASHBOARD
  • FIGURE 52. COMPETITIVE HEATMAP: THERAPEUTIC DRUG MONITORING MARKET
  • FIGURE 53. TOP PLAYER POSITIONING, 2021
  • FIGURE 54. BIO-RAD LABORATORIES, INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 55. BIO-RAD LABORATORIES, INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 56. BIO-RAD LABORATORIES, INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 57. SIEMENS AG: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 58. SIEMENS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. SIEMENS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 60. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 61. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 63. ABBOTT LABORATORIES: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 64. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 65. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 66. BIOMERIEUX SA: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 67. BIOMERIEUX SA: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 68. BIOMERIEUX SA: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 69. DANAHER CORPORATION: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 70. DANAHER CORPORATION: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 71. DANAHER CORPORATION: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 72. EXAGEN INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 73. THERMO FISHER SCIENTIFIC INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 74. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 75. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 76. SEKISUI CHEMICAL CO., LTD.: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 77. SEKISUI CHEMICAL CO., LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 78. SEKISUI CHEMICAL CO., LTD.: REVENUE SHARE BY REGION, 2021 (%)
目次
Product Code: A09152

The global therapeutic drug monitoring market was valued at $1,932.93 million in 2021 and is projected to reach $4,415.3 million by 2031, registering a CAGR of 8.5% from 2022 to 2031. Therapeutic drug monitoring (TDM) is a clinical practice in which the concentration of a specific drug in a patient's blood is measured to optimize dosage regimens, and treatment, and minimize toxicity. Therapeutic drug monitoring is used to account for individual variability in drug metabolism, minimize the risk of toxicity, identify and manage drug interactions, and improve the safety and efficacy of drug treatment. It is a valuable tool in the management of drug treatment, offering numerous advantages in terms of safety, efficacy, and personalized care. Therapeutic drug concentration is monitored through immunoassays, calorimetric immunoassays, and chromatography-mass spectrometry.

The therapeutic drug monitoring market growth is driven by the growing prevalence of chronic diseases, an increase in awareness about therapeutic drug monitoring, and a rise in demand for therapeutic drug monitoring services in emerging markets. The rise in the prevalence of chronic diseases such as cardiovascular diseases, cancer, and neurodegenerative diseases, which require long-term treatment with drugs that have a narrow therapeutic window, is driving the demand for therapeutic drug monitoring services. For instance, according to International Diabetes Federation, in 2021, it was estimated that about 537 million adults (20-79 years) are living with diabetes in the world and is expected to reach 643 million by 2030. Thus, an increase in the prevalence of chronic diseases and the need for long-term treatment is expected to boost the demand for therapeutic drug monitoring services, which, in turn, contribute toward market growth. Furthermore, the increasing demand for advanced and innovative consumables such as immunoassays is the key factor contributing to the growth of the market. For instance, Eagle Biosciences offers various therapeutic drug monitoring assays such as Alemtuzumab ELISA Assay which is used for the quantitative determination of Alemtuzumab (Lemrada) drug in in the patient's blood. However, a lack of skilled professionals present in the market, and technical errors in sample collection can limit the adoption of therapeutic drug monitoring products, which, in turn, hinders the growth of the market in upcoming years. On the other hand, increased focus on R&D activities for therapeutic drug monitoring and growth potential in emerging markets are expected to create immense opportunities for therapeutic drug monitoring during the forecast period.

The therapeutic drug monitoring market is segmented on the basis of product, technology, drug class, end user and region. As per product, the market is classified into consumables and equipment. On the basis of technology, the market is segmented into immunoassay, chromatography-spectrometry, and others. According to the drug class, the market is divided into anti-epileptic drugs, antibiotics drugs, anti-arrhythmic drugs, immunosuppressants, and others.

Depending on end-user, the market is classified into hospitals, diagnostic lab, and research and academic institutes. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA). Major key players that operate in the global therapeutic drug monitoring market are Abbott Laboratories, Biomerieux SA, Bio-Rad Laboratories, Inc., Chromsystems Instruments & Chemicals GmbH, Danaher Corporation, Exagen Inc, F. Hoffmann-La Roche Ltd., Sekisui Chemical Co Ltd., Siemens AG, and Thermo Fisher Scientific Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the therapeutic drug monitoring market analysis from 2021 to 2031 to identify the prevailing therapeutic drug monitoring market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the therapeutic drug monitoring market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global therapeutic drug monitoring market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Technology

  • Immunoassays
  • Chromatography-Spectrometry
  • Others

By Product

  • Consumables
  • Equipment

By Drug Class

  • Antiepileptic Drugs
  • Antiarrhythmic Drugs
  • Immunosuppressant Drugs
  • Antibiotic Drugs
  • Others

By End Users

  • Hospital
  • Diagnostic labs
  • Research and Academic Institutes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Biomerieux SA
  • Thermo Fisher Scientific Inc.
  • Siemens AG
  • Chromsystems Instruments & Chemicals GmbH
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • SEKISUI CHEMICAL CO., LTD.
  • Exagen Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in the prevalence of chronic disease.
      • 3.4.1.2. Rise in the adoption of precision medicine
      • 3.4.1.3. Rise in technological advancement
    • 3.4.2. Restraints
      • 3.4.2.1. Lack of skilled professionals
    • 3.4.3. Opportunities
      • 3.4.3.1. High growth potential in developing economies
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Consumables
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Equipment
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Immunoassays
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Chromatography-Spectrometry
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Antiepileptic Drugs
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Antiarrhythmic Drugs
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Immunosuppressant Drugs
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Antibiotic Drugs
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country
  • 6.6. Others
    • 6.6.1. Key market trends, growth factors and opportunities
    • 6.6.2. Market size and forecast, by region
    • 6.6.3. Market share analysis by country

CHAPTER 7: THERAPEUTIC DRUG MONITORING MARKET, BY END USERS

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Hospital
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Diagnostic labs
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Research and Academic Institutes
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country

CHAPTER 8: THERAPEUTIC DRUG MONITORING MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key trends and opportunities
    • 8.2.2. Market size and forecast, by Product
    • 8.2.3. Market size and forecast, by Technology
    • 8.2.4. Market size and forecast, by Drug Class
    • 8.2.5. Market size and forecast, by End Users
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Key market trends, growth factors and opportunities
      • 8.2.6.1.2. Market size and forecast, by Product
      • 8.2.6.1.3. Market size and forecast, by Technology
      • 8.2.6.1.4. Market size and forecast, by Drug Class
      • 8.2.6.1.5. Market size and forecast, by End Users
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Key market trends, growth factors and opportunities
      • 8.2.6.2.2. Market size and forecast, by Product
      • 8.2.6.2.3. Market size and forecast, by Technology
      • 8.2.6.2.4. Market size and forecast, by Drug Class
      • 8.2.6.2.5. Market size and forecast, by End Users
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Key market trends, growth factors and opportunities
      • 8.2.6.3.2. Market size and forecast, by Product
      • 8.2.6.3.3. Market size and forecast, by Technology
      • 8.2.6.3.4. Market size and forecast, by Drug Class
      • 8.2.6.3.5. Market size and forecast, by End Users
  • 8.3. Europe
    • 8.3.1. Key trends and opportunities
    • 8.3.2. Market size and forecast, by Product
    • 8.3.3. Market size and forecast, by Technology
    • 8.3.4. Market size and forecast, by Drug Class
    • 8.3.5. Market size and forecast, by End Users
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Key market trends, growth factors and opportunities
      • 8.3.6.1.2. Market size and forecast, by Product
      • 8.3.6.1.3. Market size and forecast, by Technology
      • 8.3.6.1.4. Market size and forecast, by Drug Class
      • 8.3.6.1.5. Market size and forecast, by End Users
      • 8.3.6.2. France
      • 8.3.6.2.1. Key market trends, growth factors and opportunities
      • 8.3.6.2.2. Market size and forecast, by Product
      • 8.3.6.2.3. Market size and forecast, by Technology
      • 8.3.6.2.4. Market size and forecast, by Drug Class
      • 8.3.6.2.5. Market size and forecast, by End Users
      • 8.3.6.3. UK
      • 8.3.6.3.1. Key market trends, growth factors and opportunities
      • 8.3.6.3.2. Market size and forecast, by Product
      • 8.3.6.3.3. Market size and forecast, by Technology
      • 8.3.6.3.4. Market size and forecast, by Drug Class
      • 8.3.6.3.5. Market size and forecast, by End Users
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Key market trends, growth factors and opportunities
      • 8.3.6.4.2. Market size and forecast, by Product
      • 8.3.6.4.3. Market size and forecast, by Technology
      • 8.3.6.4.4. Market size and forecast, by Drug Class
      • 8.3.6.4.5. Market size and forecast, by End Users
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Key market trends, growth factors and opportunities
      • 8.3.6.5.2. Market size and forecast, by Product
      • 8.3.6.5.3. Market size and forecast, by Technology
      • 8.3.6.5.4. Market size and forecast, by Drug Class
      • 8.3.6.5.5. Market size and forecast, by End Users
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Key market trends, growth factors and opportunities
      • 8.3.6.6.2. Market size and forecast, by Product
      • 8.3.6.6.3. Market size and forecast, by Technology
      • 8.3.6.6.4. Market size and forecast, by Drug Class
      • 8.3.6.6.5. Market size and forecast, by End Users
  • 8.4. Asia-Pacific
    • 8.4.1. Key trends and opportunities
    • 8.4.2. Market size and forecast, by Product
    • 8.4.3. Market size and forecast, by Technology
    • 8.4.4. Market size and forecast, by Drug Class
    • 8.4.5. Market size and forecast, by End Users
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Key market trends, growth factors and opportunities
      • 8.4.6.1.2. Market size and forecast, by Product
      • 8.4.6.1.3. Market size and forecast, by Technology
      • 8.4.6.1.4. Market size and forecast, by Drug Class
      • 8.4.6.1.5. Market size and forecast, by End Users
      • 8.4.6.2. China
      • 8.4.6.2.1. Key market trends, growth factors and opportunities
      • 8.4.6.2.2. Market size and forecast, by Product
      • 8.4.6.2.3. Market size and forecast, by Technology
      • 8.4.6.2.4. Market size and forecast, by Drug Class
      • 8.4.6.2.5. Market size and forecast, by End Users
      • 8.4.6.3. Australia
      • 8.4.6.3.1. Key market trends, growth factors and opportunities
      • 8.4.6.3.2. Market size and forecast, by Product
      • 8.4.6.3.3. Market size and forecast, by Technology
      • 8.4.6.3.4. Market size and forecast, by Drug Class
      • 8.4.6.3.5. Market size and forecast, by End Users
      • 8.4.6.4. India
      • 8.4.6.4.1. Key market trends, growth factors and opportunities
      • 8.4.6.4.2. Market size and forecast, by Product
      • 8.4.6.4.3. Market size and forecast, by Technology
      • 8.4.6.4.4. Market size and forecast, by Drug Class
      • 8.4.6.4.5. Market size and forecast, by End Users
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Key market trends, growth factors and opportunities
      • 8.4.6.5.2. Market size and forecast, by Product
      • 8.4.6.5.3. Market size and forecast, by Technology
      • 8.4.6.5.4. Market size and forecast, by Drug Class
      • 8.4.6.5.5. Market size and forecast, by End Users
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Key market trends, growth factors and opportunities
      • 8.4.6.6.2. Market size and forecast, by Product
      • 8.4.6.6.3. Market size and forecast, by Technology
      • 8.4.6.6.4. Market size and forecast, by Drug Class
      • 8.4.6.6.5. Market size and forecast, by End Users
  • 8.5. LAMEA
    • 8.5.1. Key trends and opportunities
    • 8.5.2. Market size and forecast, by Product
    • 8.5.3. Market size and forecast, by Technology
    • 8.5.4. Market size and forecast, by Drug Class
    • 8.5.5. Market size and forecast, by End Users
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Key market trends, growth factors and opportunities
      • 8.5.6.1.2. Market size and forecast, by Product
      • 8.5.6.1.3. Market size and forecast, by Technology
      • 8.5.6.1.4. Market size and forecast, by Drug Class
      • 8.5.6.1.5. Market size and forecast, by End Users
      • 8.5.6.2. Saudi Arabia
      • 8.5.6.2.1. Key market trends, growth factors and opportunities
      • 8.5.6.2.2. Market size and forecast, by Product
      • 8.5.6.2.3. Market size and forecast, by Technology
      • 8.5.6.2.4. Market size and forecast, by Drug Class
      • 8.5.6.2.5. Market size and forecast, by End Users
      • 8.5.6.3. South Africa
      • 8.5.6.3.1. Key market trends, growth factors and opportunities
      • 8.5.6.3.2. Market size and forecast, by Product
      • 8.5.6.3.3. Market size and forecast, by Technology
      • 8.5.6.3.4. Market size and forecast, by Drug Class
      • 8.5.6.3.5. Market size and forecast, by End Users
      • 8.5.6.4. Rest of LAMEA
      • 8.5.6.4.1. Key market trends, growth factors and opportunities
      • 8.5.6.4.2. Market size and forecast, by Product
      • 8.5.6.4.3. Market size and forecast, by Technology
      • 8.5.6.4.4. Market size and forecast, by Drug Class
      • 8.5.6.4.5. Market size and forecast, by End Users

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top player positioning, 2021

CHAPTER 10: COMPANY PROFILES

  • 10.1. Bio-Rad Laboratories, Inc.
    • 10.1.1. Company overview
    • 10.1.2. Key Executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Business performance
    • 10.1.7. Key strategic moves and developments
  • 10.2. Siemens AG
    • 10.2.1. Company overview
    • 10.2.2. Key Executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
  • 10.3. F. Hoffmann-La Roche Ltd.
    • 10.3.1. Company overview
    • 10.3.2. Key Executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Business performance
  • 10.4. Abbott Laboratories
    • 10.4.1. Company overview
    • 10.4.2. Key Executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
    • 10.4.6. Business performance
  • 10.5. Biomerieux SA
    • 10.5.1. Company overview
    • 10.5.2. Key Executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
    • 10.5.6. Business performance
  • 10.6. Danaher Corporation
    • 10.6.1. Company overview
    • 10.6.2. Key Executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
    • 10.6.6. Business performance
  • 10.7. Exagen Inc.
    • 10.7.1. Company overview
    • 10.7.2. Key Executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
    • 10.7.6. Business performance
  • 10.8. Thermo Fisher Scientific Inc.
    • 10.8.1. Company overview
    • 10.8.2. Key Executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
    • 10.8.6. Business performance
  • 10.9. SEKISUI CHEMICAL CO., LTD.
    • 10.9.1. Company overview
    • 10.9.2. Key Executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
    • 10.9.6. Business performance
  • 10.10. Chromsystems Instruments & Chemicals GmbH
    • 10.10.1. Company overview
    • 10.10.2. Key Executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio